Analysis of antithrombotic therapy in elderly patients with atrial fibrillation.
This study aimed to analyze the impact factors and outcome of antithrombotic therapy in elderly patients over 65 years old that suffered from atrial fibrillation (AF). A total of 256 elderly patients with AF over 65 years old were divided into 3 groups: 65-74 years old (N = 86), 75-84 years old (N = 122), and over 85 years old (N = 48). The clinical characteristics, antithrombotic therapy, and its related impact factors were retrospectively analyzed. Of all patients, 187 received antithrombotic therapy. In the 65-74 year-old group, 78 patients received antiplatelet treatment (90.7%) and 5 patients received anticoagulation treatment (5.8%). In the 75-84 year-old group, 76 patients received antiplatelet treatment (62.3%) and 14 patients received anticoagulation treatment (11.5%). In the group of over 85 year-olds, 33 patients received antiplatelet therapy (68.8%) and 4 patients received anticoagulation treatment (8.3%). Eleven patients had deep vein thrombosis and atrial thrombosis during antiplatelet therapy (5.9%), 5 patients had gastrointestinal hemorrhage after antiplatelet therapy (2.7%), 2 patients had gastrointestinal bleeding, and 3 patients had brain hemorrhage after anticoagulation treatment (21.7%). Suboptimal antithrombotic therapy was observed in the elderly patients with AF, partly owing to the risks of both thromboembolism and bleeding.